Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance

Hideki Iwamoto, Yihai Cao(Karolinska Institutet), Jieyu Wu(Nanjing University of Chinese Medicine), Takahiro Seki(Karolinska Institutet), Kayoko Hosaka(Karolinska Institutet), Masaki Nakamura(NTT Medical Center), Qingjun Zhou(Qingdao University), Yunlong Yang(Fudan University), Xiaoting Sun(Tianjin University of Traditional Chinese Medicine), Yongtian Lu(Shenzhen Second People's Hospital), Weiyun Shi(Shandong Eye Hospital), Xingkang He(Sir Run Run Shaw Hospital), Guohui Nie(Shenzhen University Health Science Center), Qi Li(First Affiliated Hospital of Zhengzhou University), Sharon Lim(Karolinska Institutet), Takuji Torimura(Omuta hospital), Mitsuhiko Abe(Kurume University), Dongmei Cui
Cell Metabolism
June 1, 2018
10.1016/j.cmet.2018.05.005
Cited by 305

Related Papers

Angiogenesis modulates adipogenesis and obesity
|Journal of Clinical Investigation|2007|733
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Genomic instability in laminopathy-based premature aging
|Nature Medicine|2005|641
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Therapeutic strategies by modulating oxygen stress in cancer and inflammation
|Advanced Drug Delivery Reviews|2009|542